

# Author Index Volume 28 (2016)

The issue number is given in front of the page numbers

- Abi-Jaoude, E., see Le Noury, J. (3) 143–161  
Afifi, S., see Peymani, P. (1) 25–31  
Alvarez, P.A., D.T. Nguyen, R. Schutt, C. Ganduglia, J.D. Estep, E.A. Graviss and D. Putney,  
In-hospital use of non-steroidal anti-inflammatory drugs in patients with heart failure  
in academic centers in the United States (4) 181–188  
Amsterdam, J.D., see Jureidini, J.N. (1) 33–43  
Awodele, O., A. Ibrahim and P. Orhii, Patterns of adverse drug reaction signals in NAFDAC  
Pharmacovigilance activities from September to November, 2014 (1) 13–23  
  
Baldo, V., see Buja, A. (3) 163–170  
Bassi, P., see Ogunleye, O.O. (2) 77–91  
Buja, A., A.M. Saieva, A. Vinelli, R.M. Cacco, K. Ottolitri, E. De Battisti, C. Dario and  
V. Baldo, Adverse event reporting and patient safety at a University Hospital: Mapping,  
correlating and associating events for a data-based patient risk management (3) 163–170  
  
Cacco, R.M., see Buja, A. (3) 163–170  
Cohen, D., see Hughes, S. (2) 101–114  
Cruz, R.S., see dos Reis, C. (1) 45–60  
  
Danborg, P.B., see Simonsen, A.L. (1) 1–12  
Dario, C., see Buja, A. (3) 163–170  
De Battisti, E., see Buja, A. (3) 163–170  
Dias, J.J., see Mehta, S. (2) 65–75  
dos Reis, C., R. Teixo, F. Mendes and R.S. Cruz, Biosimilar medicines – Review (1) 45–60  
  
Ekoja, M., see Ogunleye, O.O. (2) 77–91  
El-Enein, N.Y.A., see Zaghoul, A.A. (2) 93–99  
Enwere, O., see Ogunleye, O.O. (2) 77–91  
Estep, J.D., see Alvarez, P.A. (4) 181–188  
  
Falade, C., see Ogunleye, O.O. (2) 77–91  
  
Ganduglia, C., see Alvarez, P.A. (4) 181–188  
Gøtzsche, P.C., see Simonsen, A.L. (1) 1–12  
Graviss, E.A., see Alvarez, P.A. (4) 181–188  
Grech, V., Response to a Letter to the Editor (3) 175–176  
  
Healy, D., J. Le Noury and D. Mangin, Links between serotonin reuptake inhibition during  
pregnancy and neurodevelopmental delay/spectrum disorders: A systematic review of  
epidemiological and physiological evidence (3) 125–141  
Healy, D., see Le Noury, J. (3) 143–161

- Heydari, S.T., see Peymani, P. (1) 25–31
- Hughes, S., D. Cohen and R. Johnson, Adverse event assessment methods in published trials of psychotropic drugs: Poor reporting and neglect of emerging safety concerns (2) 101–114
- Ibrahim, A., see Awodele, O. (1) 13–23
- Isah, A., see Ogunleye, O.O. (2) 77–91
- Jargin, S.V., Concerning a Letter to the Editor (3) 171–174
- Johnson, R., see Hughes, S. (2) 101–114
- Jørgensen, K.J., see Ziganshina, L.E. (4) 221–226
- Jureidini, J., see Le Noury, J. (3) 143–161
- Jureidini, J.N., J.D. Amsterdam and L.B. McHenry, The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance (1) 33–43
- Kapp, M.B., Defensive medicine: No wonder policymakers are confused (4) 213–219
- Kapp, M.B., Front office staff as medical educators, risk creators, and risk managers (1) 61–64
- Kilani, J., see Ogunleye, O.O. (2) 77–91
- Kolfschoten, J., see Rolfes, L. (2) 115–123
- Kooijman, M., see Rolfes, L. (2) 115–123
- Kwon, C.S., E. Seoane-Vazquez and R. Rodriguez-Monguio, FDA safety actions for antidiabetic drugs marketed in the US, 1980–2015 (4) 197–211
- Lankarani, K.B., see Peymani, P. (1) 25–31
- Le Noury, J., J.M. Nardo, D. Healy, J. Jureidini, M. Raven, C. Tufanaru and E. Abi-Jaoude, Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression (3) 143–161
- Le Noury, J., see Healy, D. (3) 125–141
- Maharlouei, N., see Peymani, P. (1) 25–31
- Mangin, D., see Healy, D. (3) 125–141
- McHenry, L.B., see Jureidini, J.N. (1) 33–43
- Mehta, S., H.P. Singh and J.J. Dias, Effect of patient safety incident review and reflection in an extended morbidity and mortality meeting (2) 65–75
- Mendes, F., see dos Reis, C. (1) 45–60
- Namazi, S., see Peymani, P. (1) 25–31
- Nardo, J.M., see Le Noury, J. (3) 143–161
- Nguyen, D.T., see Alvarez, P.A. (4) 181–188
- Nouraei, H., see Peymani, P. (1) 25–31
- Obiako, R., see Ogunleye, O.O. (2) 77–91
- Obodo, J., see Ogunleye, O.O. (2) 77–91
- Odesanya, R., see Ogunleye, O.O. (2) 77–91
- Ogundele, S.O., see Ogunleye, O.O. (2) 77–91
- Ogunleye, O.O., I.A. Oreagba, C. Falade, A. Isah, O. Enwere, S. Olayemi, S.O. Ogundele, R. Obiako, R. Odesanya, P. Bassi, J. Obodo, J. Kilani and M. Ekoja, Medication errors among health professionals in Nigeria: A national survey (2) 77–91

- Olayemi, S., see Ogunleye, O.O. (2) 77–91
- Oreagba, I.A., see Ogunleye, O.O. (2) 77–91
- Orhii, P., see Awodele, O. (1) 13–23
- Ottolitri, K., see Buja, A. (3) 163–170
- Peymani, P., R. Tabrizi, S. Afifi, S. Namazi, S.T. Heydari, M.K. Shirazi, H. Nouraei, E. Sadeghi, K.B. Lankarani and N. Maharlouei, Knowledge, attitude and practice of General Practitioners towards adverse drug reaction reporting in South of Iran, Shiraz (Pharmacoepidemiology report) (1) 25–31
- Putney, D., see Alvarez, P.A. (4) 181–188
- Rahman, S.A., see Zaghoul, A.A. (2) 93–99
- Raven, M., see Le Noury, J. (3) 143–161
- Rodriguez-Monguio, R., see Kwon, C.S. (4) 197–211
- Rolfes, L., J. Kolfshoten, F. van Hunsel, M. Kooijman and E. van Puijenbroek, Actions in response to drug safety signals arising from a spontaneous reporting system: Retrospective study in The Netherlands (2) 115–123
- Sadeghi, E., see Peymani, P. (1) 25–31
- Saieva, A.M., see Buja, A. (3) 163–170
- Scherb, H., Comment on a Letter to the Editor (3) 177–180
- Schutt, R., see Alvarez, P.A. (4) 181–188
- Seoane-Vazquez, E., see Kwon, C.S. (4) 197–211
- Shirazi, M.K., see Peymani, P. (1) 25–31
- Simonsen, A.L., P.B. Danborg and P.C. Gøtzsche, Persistent sexual dysfunction after early exposure to SSRIs: Systematic review of animal studies (1) 1–12
- Singh, H.P., see Mehta, S. (2) 65–75
- Tabrizi, R., see Peymani, P. (1) 25–31
- Teixo, R., see dos Reis, C. (1) 45–60
- Tufanaru, C., see Le Noury, J. (3) 143–161
- van Hunsel, F., see Rolfes, L. (2) 115–123
- van Puijenbroek, E., see Rolfes, L. (2) 115–123
- Vinelli, A., see Buja, A. (3) 163–170
- Yaxley, J., Common analgesic agents and their role in analgesic nephropathy: A commentary of the evidence (4) 189–196
- Zaghoul, A.A., S.A. Rahman and N.Y.A. El-Enein, Obligation towards medical errors disclosure at a tertiary care hospital in Dubai, UAE (2) 93–99
- Ziganshina, L.E. and K.J. Jørgensen, The first ever Cochrane event in Russia and Russian speaking countries – Cochrane Russia Launch – Evidence-based medicine: Achievements and barriers (QiQUM 2015) International Conference, Kazan, December 7-8, 2015 (4) 221–226